According to a new report by Polaris Market Research, the global castrate-resistant prostate cancer (CRPC) market was valued at USD 12.92 billion in 2024 and is projected to reach USD 29.79 billion by 2034, expanding at a CAGR of 8.7% from 2025 to 2034. Growth is underpinned by rising prostate cancer incidence, an expanding geriatric population, and accelerating innovation in hormonal...